Genomic instability, a hallmark of cancer, has been targeted by treatments from chemotherapy and radiation to PARP inhibitors for repair-deficient tumors, and more recently to antibody-drug conjugates and radiopharmaceuticals. Precision medicine targeting genomic instability now emphasizes patient selection and rational drug combinations, expanding the therapeutic index for better outcomes.